Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity
Source abstract
Abstract
Macromolecular prodrugs are developed as multiarmed agents against diverse viral pathogens. Lead candidates inhibit infectivity and replication of HIV, Ebola, influenza, measles, RSV, etc—thus being broad-spectrum antiviral agents. As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: HIV Research and Treatment · Respiratory viral infections research · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
CSIRO‐Health and Biosecurity Flagship Australian Animal Health Laboratory Geelong VIC 3220 Australia
Department of Infectious Diseases Aarhus University Hospital 8000 Aarhus C Denmark
Department of Chemistry and the iNano, Interdisciplinary Nanoscience Centre Aarhus University 8000 Aarhus C Denmark
Funding
Danish Council for Independent Research, Technology and Production Sciences
References (40)
Show source-provided references
1. 10.1126/scitranslmed.300987210.1126/scitranslmed.3009872 ↗
2. 10.1016/S0140-6736(12)61728-010.1016/S0140-6736(12)61728-0 ↗
3. 10.1016/j.vaccine.2007.03.04610.1016/j.vaccine.2007.03.046 ↗
4. World Bank Group 2014 The economic impact of the 2014 Ebola epidemic: Short and medium term estimates for West Africa. Washington DC: World Bank Group.http://documents.worldbank.org/curated/en/2014/10/20270083/economic‐impact‐2014‐ebola‐epidemic‐short‐medium‐term‐estimates‐west‐africa.
5. Dixon M. G. · MMWR Morb. Mortal. Wkly. Rep. · 2014 · 63 · 548
6. 10.1126/science.aaa377810.1126/science.aaa3778 ↗
7. 10.1038/nrd248510.1038/nrd2485 ↗
8. 10.1038/nrd452910.1038/nrd4529 ↗
9. 10.1039/C4PY00624K10.1039/C4PY00624K ↗
10. Desomer P. · J. Virol. · 1968 · 2 · 87810.1128/jvi.2.9.878-885.1968 ↗
11. Desomer P. · J. Virol. · 1968 · 2 · 88610.1128/jvi.2.9.886-893.1968 ↗
12. 10.1016/j.antiviral.2011.03.17610.1016/j.antiviral.2011.03.176 ↗
13. 10.1177/09563202000110040110.1177/095632020001100401 ↗
14. 10.1016/j.antiviral.2010.09.00210.1016/j.antiviral.2010.09.002 ↗
15. 10.1128/JVI.02622-0610.1128/JVI.02622-06 ↗
16. 10.1128/jvi.65.3.1543-1550.199110.1128/jvi.65.3.1543-1550.1991 ↗
17. 10.1002/adhm.20140014810.1002/adhm.201400148 ↗
18. 10.1021/jm00013a01910.1021/jm00013a019 ↗
19. 10.1039/c3cc00315a10.1039/c3cc00315a ↗
20. 10.1002/adhm.20130063710.1002/adhm.201300637 ↗
21. 10.1016/j.jconrel.2014.09.03210.1016/j.jconrel.2014.09.032 ↗
22. 10.1016/j.jconrel.2015.04.01610.1016/j.jconrel.2015.04.016 ↗
23. 10.1038/nrd217510.1038/nrd2175 ↗
24. 10.1002/rmv.48310.1002/rmv.483 ↗
25. 10.1038/nrd242410.1038/nrd2424 ↗
26. 10.1002/adhm.20140030710.1002/adhm.201400307 ↗
27. 10.1038/nrd246810.1038/nrd2468 ↗
28. 10.1016/S0169-409X(02)00179-510.1016/S0169-409X(02)00179-5 ↗
29. 10.1021/cr300358b10.1021/cr300358b ↗
30. 10.1002/adhm.20150034410.1002/adhm.201500344 ↗
31. 10.1016/0163-7258(79)90058-510.1016/0163-7258(79)90058-5 ↗
32. 10.1016/0163-4453(90)91094-T10.1016/0163-4453(90)91094-T ↗
33. 10.1128/AAC.15.3.35610.1128/AAC.15.3.356 ↗
34. 10.1016/0166-3542(90)90029-710.1016/0166-3542(90)90029-7 ↗
35. 10.1128/JVI.01394-1310.1128/JVI.01394-13 ↗
36. 10.1002/jbm.1015210.1002/jbm.10152 ↗
37. 10.1016/j.addr.2007.04.01910.1016/j.addr.2007.04.019 ↗
38. 10.1039/C4SC02754J10.1039/C4SC02754J ↗
39. 10.1002/mabi.20130024410.1002/mabi.201300244 ↗
40. Reed L. J. M. · Am. J. Hyg. · 1938 · 27 · 493